Nuvectis Pharma
NVCT
19.85
-0.44
-2.17%
Nuvectis Pharma
US · NVCT
#3557 by market cap
Listed 2022
19.85
-0.44
-2.17%
Live - 5344 symbols - heartbeat 239s ago
· 2026-10-08 10:11
After-hours
20.29
0.00%
- Market cap
- 647.98M
- P/E (TTM)i
- -15.04
- P/Bi
- 71.40
- EPSi
- -1.32
- Div yieldi
- 0.00%
- 52W posi
- 60%
Reader sentiment
Are you bullish or bearish on NVCT?
Anonymous reader poll. Unscientific, not investment advice.
Revenue annual, last 6 years
Income statement
| Line item | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- | -- |
| Gross profit | -- | -- | -- | -- | -- | -- |
| Selling & admin expenses | -- | 3.35M | 6.01M | 7.52M | 6.93M | 9.42M |
| Research & development | -- | 9.55M | 13.23M | 15.38M | 12.92M | 18.15M |
| Operating profit | -- | -12.89M | -19.23M | -22.90M | -19.85M | -27.57M |
| Pretax profit | -- | -12.89M | -19.09M | -22.26M | -19.00M | -26.44M |
| Tax | -- | -- | -- | -- | -- | -- |
| Net profit | -- | -12.89M | -19.09M | -22.26M | -19.00M | -26.44M |
| Basic EPS | -- | -1 | -2 | -1 | -1 | -1 |
| Diluted EPS | -- | -1.09 | -1.51 | -1.43 | -1.11 | -1.32 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- | -- |
| Gross profit | -- | -- | -- | -- | -- | -- |
| Selling & admin expenses | 1.89M | 2.98M | 2.02M | 2.53M | 2.15M | 2.51M |
| Research & development | 3.68M | 3.61M | 5.77M | 5.09M | 4.11M | 4.68M |
| Operating profit | -5.57M | -6.60M | -7.79M | -7.62M | -6.26M | -7.20M |
| Pretax profit | -5.33M | -6.33M | -7.46M | -7.31M | -6.05M | -7.02M |
| Tax | -- | -- | -- | -- | -- | -- |
| Net profit | -5.33M | -6.33M | -7.46M | -7.31M | -6.05M | -7.02M |
| Basic EPS | 0 | 0 | 0 | 0 | 0 | 0 |
| Diluted EPS | -0.27 | -0.30 | -0.44 | -0.31 | -0.26 | -0.30 |
Balance sheet
| Line item | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Total current assets | 0 | 5.83M | 20.41M | 19.19M | 18.61M | 31.71M |
| Cash & ST investments | 0 | 5.74M | 19.99M | 19.13M | 18.53M | 31.63M |
| Inventory | -- | -- | -- | -- | -- | -- |
| Total assets | 0 | 6.66M | 20.41M | 19.19M | 18.61M | 31.71M |
| Total current liabilities | 10.00K | 2.42M | 6.19M | 6.98M | 8.89M | 13.30M |
| Short-term debt | -- | -- | -- | -- | -- | -- |
| Long-term debt | -- | -- | -- | -- | -- | -- |
| Total liabilities | 10,000.00 | 17,665,000.00 | 6,186,000.00 | 6,984,000.00 | 8,894,000.00 | 13,296,000.00 |
| Total equity | -10.00K | -11.01M | 14.22M | 12.20M | 9.71M | 18.41M |
| Retained earnings | -10.00K | -12.90M | -31.99M | -54.25M | -73.25M | -99.69M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 30.15M | 27.01M | 35.59M | 31.71M | 25.40M | 22.38M |
| Cash & ST investments | 29.86M | 26.79M | 35.44M | 31.63M | 25.13M | 22.16M |
| Inventory | -- | -- | -- | -- | -- | -- |
| Total assets | 30.15M | 27.01M | 35.59M | 31.71M | 25.40M | 22.38M |
| Total current liabilities | 9.19M | 10.14M | 11.58M | 13.30M | 11.18M | 13.29M |
| Short-term debt | -- | -- | -- | -- | -- | -- |
| Long-term debt | -- | -- | -- | -- | -- | -- |
| Total liabilities | 9,194,000.00 | 10,135,000.00 | 11,577,000.00 | 13,296,000.00 | 11,178,000.00 | 13,294,000.00 |
| Total equity | 20.95M | 16.87M | 24.01M | 18.41M | 14.22M | 9.08M |
| Retained earnings | -78.58M | -84.91M | -92.37M | -99.69M | -105.74M | -112.76M |
Cash flow
| Line item | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Operating cash flow | -- | -9.50M | -13.56M | -15.95M | -12.25M | -16.01M |
| Depreciation & amortization | -- | -- | -- | -- | -- | -- |
| Free cash flow | -- | -9.50M | -13.56M | -15.95M | -12.25M | -16.01M |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | -- | 0 | 31.88M | 5.29M | 12.04M | 31.21M |
| Ending cash balance | -- | 5.74M | 19.99M | 19.13M | 18.53M | 31.63M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | -4.17M | -3.37M | -4.49M | -3.97M | -6.51M | -4.53M |
| Depreciation & amortization | -- | -- | -- | -- | -- | -- |
| Free cash flow | -4.17M | -3.37M | -4.49M | -3.97M | -6.51M | -4.53M |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | 16.80M | 614.00K | 13.55M | 248.00K | 7.00K | 1.57M |
| Ending cash balance | 29.86M | 26.79M | 35.44M | 31.63M | 25.13M | 22.16M |
Returns & efficiency
| Line item | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| ROE %i | -- | -- | -1,188.73 | -168.51 | -173.41 | -205.30 |
| ROA %i | -- | -387.26 | -141.05 | -112.45 | -100.55 | -114.76 |
| ROIC %i | -- | -- | -1,198.01 | -173.33 | -181.14 | -213.35 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | -- | -- | -- | -- | -- | -- |
| FCF / sales %i | -- | -- | -- | -- | -- | -- |
| Current ratioi | -- | 2.41 | 3.30 | 2.75 | 2.09 | 2.38 |
| Quick ratioi | -- | 2.37 | 3.23 | 2.74 | 2.08 | 2.38 |
| Debt / assetsi | -- | -- | -- | -- | -- | -- |
| LT debt / equityi | -- | -- | -- | -- | -- | -- |
| Interest coveragei | -- | -- | -- | -- | -- | -- |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | 0.00 | 0.00 |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | -115.28 | -150.12 | -158.88 | -205.30 | -168.24 | -233.30 |
| ROA %i | -80.87 | -97.42 | -105.13 | -114.76 | -106.54 | -122.61 |
| ROIC %i | -120.19 | -156.27 | -164.77 | -213.35 | -174.53 | -241.17 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | -- | -- | -- | -- | -- | -- |
| FCF / sales %i | -- | -- | -- | -- | -- | -- |
| Current ratioi | 3.28 | 2.66 | 3.07 | 2.38 | 2.27 | 1.68 |
| Quick ratioi | 3.25 | 2.64 | 3.06 | 2.38 | 2.25 | 1.67 |
| Debt / assetsi | -- | -- | -- | -- | -- | -- |
| LT debt / equityi | -- | -- | -- | -- | -- | -- |
| Interest coveragei | -- | -- | -- | -- | -- | -- |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
Quote time 2026-10-08 10:11:01 · For reference only, not investment advice and not tailored to your situation.